Quantcast

Latest Non-Hodgkin lymphoma Stories

2014-06-10 08:30:25

CAMBRIDGE, Mass., June 10, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that an abstract on EPZ-6438 has been accepted for oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology, to be held August 10-13 in Colorado Springs, Colorado. The presentation will include findings characterizing the...

2014-06-09 14:34:42

Rockefeller University Press A new study in The Journal of Experimental Medicine reveals that a high-risk group of patients with follicular lymphoma could benefit from a novel drug combination. Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are...

2014-06-02 23:05:52

Transparency Market Research added a new report "Global Natural Killer Cell Lymphomas Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/natural-killer-cell-lymphomas.html. Albany, New York (PRWEB) June 02, 2014 Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner. There are two types of lymphomas- Hodgkin’s and...

2014-05-15 12:28:11

Blair, Ph.D., testifies how God enabled him to live cancer-free, without treatment MAITLAND, Fla., May 15, 2014 /PRNewswire-iReach/ -- In his new book, God's Cure For Cancer: No chemotherapy, No radiation, No surgery ($14.99, paperback, 9781629522029; $6.99, e-book, 9781629522036) Weston L. Blair, Ph.D. tells the remarkable story of how God healed him from Stage 4 Non-Hodgkin's Lymphoma. The author's full recovery was made possible only through the Word of God. Furthermore, he was...

2014-04-29 16:25:50

Blair, Ph.D., testifies how God enabled him to live cancer-free, without treatment MAITLAND, Fla., April 29, 2014 /PRNewswire-iReach/ -- In his new book, God's Cure For Cancer: No chemotherapy, No radiation, No surgery ($12.99, paperback, 9781629522029; $6.99, e-book, 9781629522036) Weston L. Blair, Ph.D. tells the remarkable story of how God healed him from Stage 4 Non-Hodgkin's Lymphoma. The author's full recovery was made possible only through the Word of God. Furthermore, he was...

2014-04-29 04:21:45

- First and Only Approved Monotherapy in the EU for this Patient Population - BIRMINGHAM, England, April 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54(th) annual scientific meeting of the British Society for Haematology. PIXUVRI...

2014-04-24 08:33:54

Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related